Clinical trial NCT04577937: Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Official title: Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lymphangioleiomyomatosis
Sleep Disorder
Sleep Apnea Syndromes
Hypopnea Syndrome
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2020-10-08
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: cohort study, pilot
Primary purpose: SCREENING

Brief summary: Lymphangioleiomyomatosis (LAM) is a rare and progressive pulmonary disease of unknown etiology that almost exclusively affects women. It is characterised by cystic radiological lung pattern and by the possible presence of angiomyolipomas in other sites or organs. Functionally LAM is associated with airway obstruction or restriction and progressive hypoxemia up to chronic respiratory failure.

There are no studies, so far, which have investigated whether during sleep these patients show changes in the sleep profile and gas exchange and if these changes are related to disease severity. Aim of the study, prospective and pilot, is to evaluate whether the physiological modification of respiratory mechanics during sleep is associated with polysomnographic alterations in LAM.

Detailed description: Lymphangioleiomiomatosis (LAM) is a rare progressive disease that affects primarily lungs with a cystic radiologic pattern and may be associated with angiomiolipomas in the kidneys or in other sites and an increased frequency of meningioma. Patients with sporadic LAM are usually female (incidence around 1/400.000 adult females). LAM associated with tuberous sclerosis may affect male, female and children.

LAM patients are functionally characterized by obstructive or restrictive syndrome that leads patients to hypoxemia and chronic respiratory failure, so that quality of Life (QoL) of these patients is affected by dyspnea. Hypoxemia contributes to the development of secondary pulmonary hypertension (PH) during progression of LAM history, worsening the damage.

The modifications in the neural control of ventilation during sleep in combination with anatomical disposition drive to sleep-related changes in upper airway resistance and physiologic desaturations. In healthy subjects these features are almost completely compensated but, in LAM patients, may lead to airway obstruction and/or pathologic oxygen desaturation that could be managed. So far, none have investigated the changes in sleep architecture and related blood gas exchange in patients with LAM relating these changes with disease severity.

This pilot study investigate if the physiologic modifications of breathing during sleep lead to sleep disorders in LAM patients, measured through abnormalities in polysomnography (PSG) and ih sleep disorders in LAM are associated with respiratory functional abnormalities and disease severity.

Eligibility criteria: Inclusion Criteria:

* confirmed diagnosis of LAM according to current guidelines
* sign of informed consent to participate

Exclusion Criteria:

* the presence of either acute or chronic respiratory failure
* the use of long-term oxygen therapy

Primary outcomes:
measure: prevalence of sleep disorders in LAM
timeFrame: 1 year
measure: correlation between sleep-related disorders and LAM severity measured by spirometry
timeFrame: 1 year
measure: correlation between sleep-related disorders and LAM severity measured by annual decline of forced-expiratory volume at the first second (FEV1)
timeFrame: 1 year
measure: correlation between sleep-related disorders and LAM severity measured by arterial blood gas exchange
timeFrame: 1 year
measure: correlation between sleep-related disorders and clincal parameters
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Azienda Ospedaliero-Universitaria di Bologna
Study officials:
affiliation: AOSP - Azienda Ospedaliero Universitaria Di Bologna
name: Stefano Nava, MD-FERS
role: PRINCIPAL_INVESTIGATOR
References: